in pursuit of allogeneic adoptive cell therapies to cure cancer
We are a clinical stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses. Our iNKT cells, which we refer to as INTELLIGENT iNKT™ cells, are designed to have the innate capacity to home to the site of diseased tissue, including cancer, and recruit key components of the immune system to fight disease. iNKT cells combine properties of both T and natural killer (NK) cells and tune their response based on individual elements of the tumor or disease microenvironment. Our development pipeline includes off-the-shelf iNKT cell product candidates to treat hematologic and solid tumors. We believe these product candidates have the potential to help us treat a significantly larger patient population than is currently served by autologous Chimeric Antigen Receptor T, also known as CAR-T cell therapy.
AgenTus Therapeutics was formed in 2017 as a subsidiary of Agenus Inc. to accelerate the development of allogeneic adoptive cell therapies.
Today we are more than 25 people working across the U.S. and the U.K. Our expert scientists are working with world leading academic and commercial institutions to pioneer the delivery of living drugs to change the lives of cancer patients.
Our mission is to change lives by providing patients around the world with best-in-class living drugs that bring faster treatment timelines and better tumor targeting for a wide range of cancers.